Search results for "Animal"

showing 10 items of 22159 documents

A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous oxidative DNA b…

2002

The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (ste…

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchDNA RepairTranscription GeneticDNA damageDNA repairBiologyGene productMicechemistry.chemical_compoundGeneticsAnimalsPoly-ADP-Ribose Binding ProteinsMolecular BiologyGeneDNA PrimersMice KnockoutBase SequenceHomozygoteDNA HelicasesDeoxyguanosinenutritional and metabolic diseasesBase excision repairMolecular biologyOxidative StressDNA Repair EnzymesBiochemistrychemistry8-Hydroxy-2'-DeoxyguanosineDNA glycosylaseDNADNA DamageNucleotide excision repairOncogene
researchProduct

The effects of post-translational processing on dystroglycan synthesis and trafficking1

2003

Dystroglycan is a component of the dystrophin glycoprotein complex that is cleaved into two polypeptides by an unidentified protease. To determine the role of post-translational processing on dystroglycan synthesis and trafficking we expressed the dystroglycan precursor and mutants thereof in a heterologous system. A point mutant in the processing site, S655A, prevented proteolytic cleavage but had no effect upon the surface localisation of dystroglycan. Mutation of two N-linked glycosylation sites that flank the cleavage site inhibited proteolytic processing of the precursor. Furthermore, chemical inhibition of N- and O-linked glycosylation interfered with the processing of the precursor a…

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesanimal structuresCOS cellsGlycosylationbiologyLactacystinBiophysicsCell Biologymusculoskeletal systemCleavage (embryo)BiochemistryDystroglycanschemistry.chemical_compoundchemistryBiochemistryStructural BiologyGeneticsbiology.proteinDystroglycanPikachurinBinding sitetissuesMolecular BiologyFEBS Letters
researchProduct

Development of the first marmoset-specific DNA microarray (EUMAMA): a new genetic tool for large-scale expression profiling in a non-human primate

2007

Abstract Background The common marmoset monkey (Callithrix jacchus), a small non-endangered New World primate native to eastern Brazil, is becoming increasingly used as a non-human primate model in biomedical research, drug development and safety assessment. In contrast to the growing interest for the marmoset as an animal model, the molecular tools for genetic analysis are extremely limited. Results Here we report the development of the first marmoset-specific oligonucleotide microarray (EUMAMA) containing probe sets targeting 1541 different marmoset transcripts expressed in hippocampus. These 1541 transcripts represent a wide variety of different functional gene classes. Hybridisation of …

musculoskeletal diseasesendocrine systemanimal structuresMicroarraylcsh:QH426-470Energy and redox metabolism [NCMLS 4]Bioinformaticslcsh:BiotechnologyMolecular Sequence DataComputational biologyBiologyHippocampus03 medical and health sciences0302 clinical medicinebiology.animallcsh:TP248.13-248.65Gene expressionGeneticsAnimalsBiotinylationTissue DistributionOligonucleotide Array Sequence Analysis030304 developmental biologyExpressed Sequence TagsGenetics0303 health sciencesExpressed sequence tagGenomeGene Expression ProfilingNucleic Acid HybridizationMarmosetCallithrixbiology.organism_classificationCallithrixGene expression profilinglcsh:GeneticsMitochondrial medicine [IGMD 8]Gene Expression RegulationGenetic TechniquesGenBankRNADNA microarrayCellular energy metabolism [UMCN 5.3]human activities030217 neurology & neurosurgeryResearch ArticleBiotechnology
researchProduct

mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts

2011

Abstract Background Conventional high-grade osteosarcoma is a primary malignant bone tumor, which is most prevalent in adolescence. Survival rates of osteosarcoma patients have not improved significantly in the last 25 years. Aiming to increase this survival rate, a variety of model systems are used to study osteosarcomagenesis and to test new therapeutic agents. Such model systems are typically generated from an osteosarcoma primary tumor, but undergo many changes due to culturing or interactions with a different host species, which may result in differences in gene expression between primary tumor cells, and tumor cells from the model system. We aimed to investigate whether gene expressio…

musculoskeletal diseaseslcsh:Internal medicinelcsh:QH426-470Transplantation HeterologousHeterologousBone NeoplasmsBiologyMiceCell Line TumorGene expressionDatabases GeneticGeneticsmedicineAnimalsHumansGenetics(clinical)RNA Messengerlcsh:RC31-1245Survival rateneoplasmsGenetics (clinical)Oligonucleotide Array Sequence AnalysisOsteosarcomaGene Expression Profilingmedicine.diseasePrimary tumorMolecular biologyTransplantationGene expression profilinglcsh:GeneticsCell cultureCancer researchOsteosarcomaResearch ArticleBMC Medical Genomics
researchProduct

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

2012

Adeno-associated virus (AAV)-U7-mediated skipping of dystrophin-exon-23 restores dystrophin expression and muscle function in the mdx mouse model of Duchenne muscular dystrophy. Soluble activin receptor IIB (sActRIIB-Fc) inhibits signaling of myostatin and homologous molecules and increases muscle mass and function of wild-type and mdx mice. We hypothesized that combined treatment with AAV-U7 and sActRIIB-Fc may synergistically improve mdx muscle function. Bioactivity of sActRIIB-Fc on skeletal muscle was first demonstrated in wild-type mice. In mdx mice we show that AAV-U7-mediated dystrophin restoration improved specific muscle force and resistance to eccentric contractions when applied a…

musculoskeletal diseasesmdx mousemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesDuchenne muscular dystrophyActivin Receptors Type IIGenetic VectorsMyostatinBiologyDystrophin03 medical and health sciencesMice0302 clinical medicineInternal medicineGeneticsmedicineMyocyteAnimalsMuscular dystrophyMuscle SkeletalMolecular Biology030304 developmental biology0303 health sciencesBody WeightSkeletal muscleExonsGenetic TherapyDependovirusMuscular Dystrophy Animalmedicine.diseasemusculoskeletal system3. Good healthMice Inbred C57BLEndocrinologymedicine.anatomical_structureImmunologybiology.proteinMice Inbred mdxMolecular MedicineITGA7Dystrophin030217 neurology & neurosurgeryMuscle ContractionHuman gene therapy
researchProduct

Reaction of the bone structure to methotrexate-Palacos flow y. Experimental investigations in animals.

1989

With the combined osteosynthesis of pathological fractures in association with tumors and/or metastases in mind, E. Merck (Darmstadt, FRG) developed a bone cement containing a cytostatic agent, methotrexate-Palacos flow y (MTX-Pf). The animal-experimental study presented here investigates the tolerability of MTX-Pf in the femurs of rabbits with lateral comparison. In these investigations we used both the concentration of 0.63% MTX, as is currently used in standard clinical surgery, as well as a much higher concentration of 2.5% MTX. The histological sections were investigated using microradiographic methods and provided no indication of any significant differences between the femora with th…

musculoskeletal diseasesmedicine.medical_specialtyBone and BonesFractures BoneMedicineAnimalsOrthopedics and Sports Medicineskin and connective tissue diseasesWound HealingOsteosynthesisbusiness.industryBone CementsGeneral MedicineBone cementSurgeryFracture Fixation IntramedullaryMethotrexateTolerabilityOrthopedic surgerySurgeryMethotrexateRabbitsPathological fracturesbusinessBone structuremedicine.drugArchives of orthopaedic and trauma surgery
researchProduct

The PROMISE study protocol: a multicenter prospective study of process optimization with interdisciplinary and cross-sectoral care for German patient…

2021

Background and purpose — Knee and hip replacement are common and increasing procedures, and an optimized care process that could be implemented in different settings would be useful. The PROMISE trial investigates whether a new care process works equally in different German settings and how the results compare with current non-standardized care. Patients and methods — This multi-center prospective mixed-method study includes 2,000 German patients receiving arthritis-related hip or knee endoprostheses. An interdisciplinary and cross-sectoral care process was developed and implemented in 3 German hospitals with different levels of care, and corresponding rehabilitation centers were included t…

musculoskeletal diseasesmedicine.medical_specialtyCare processArthroplasty Replacement HipMEDLINEHip replacement (animal)German03 medical and health sciencesDisability Evaluation0302 clinical medicineGermanySurveys and QuestionnairesmedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineProspective StudiesProspective cohort studyArthroplasty Replacement KneePain MeasurementProtocol (science)Orthopedic surgeryPatient Care Team030222 orthopedicsbusiness.industryGeneral MedicineProstheses and Implantslanguage.human_languageTreatment OutcomeCross sectorallanguagePhysical therapyQuality of LifeSurgerybusinessRD701-811Research ArticleActa Orthopaedica
researchProduct

Evaluation of efficacy and biocompatibility of a new absorbable synthetic substitute as a dural onlay graft in a large animal model.

2016

Numerous dura substitutes are commercially available, but no absorbable synthetic dura repair product has been used for both onlay and suture applications.The safety and effectiveness of a new absorbable synthetic substitute composed of Poly-L-lactide microfibers as onlay dural graft were evaluated.Physical properties and performance of the microfibrous synthetic dural substitute implanted as an onlay or suturable grafts were compared with these commercial products, including CODMAN ETHISORB™ Dura Patch and DuraGen™ Dural Graft Matrix, in a canine duraplasty model. The cerebrospinal fluid (CSF) leakage, macroscopic and microscopic observation at 30 and 90 days after implantation were invest…

musculoskeletal diseasesmedicine.medical_specialtyTime FactorsBiocompatibilityPolyesters02 engineering and technologyDural graftIn Vitro Techniques03 medical and health sciences0302 clinical medicineDogsDural substitutemedicineAnimalsCsf leakageCerebrospinal Fluid Leakbusiness.industryGeneral Medicine021001 nanoscience & nanotechnologynervous system diseasesSurgeryMicroscopic observationDisease Models AnimalNeurologyInlaysNeurology (clinical)Dura Mater0210 nano-technologybusiness030217 neurology & neurosurgeryLarge animalNeurological research
researchProduct

Patient-specific computational evaluation of stiffness distribution in ascending thoracic aortic aneurysm

2021

Quantifying local aortic stiffness properties in vivo is acknowledged as essential to assess the severity of an ascending thoracic aortic aneurysm (ATAA). Recently, the LESI (local extensional stiffness identification) methodology has been established to quantify non-invasively local stiffness properties of ATAAs using electrocardiographic-gated computed tomography (ECG-gated CT) scans. The aim of the current study was to determine the most sensitive markers of local ATAA stiffness estimation with the hypothesis that direct measures of local ATAA stiffness could better detect the high-risk patients. A cohort of 30 patients (12 BAV and 18 TAV) referred for aortic size evaluation by ECG-gated…

musculoskeletal diseasesmedicine.medical_specialtyanimal structuresBicuspid aortic valveExtensional stiffness0206 medical engineeringBiomedical EngineeringBiophysicsHemodynamicsmacromolecular substances02 engineering and technologyPositive correlationThoracic aortic aneurysm03 medical and health sciencesVascular Stiffness0302 clinical medicineBicuspid aortic valveInternal medicinemedicineHumansOrthopedics and Sports MedicineAortic Pulse PressureAortaComputingMilieux_MISCELLANEOUSShear stressAortic Aneurysm Thoracicbusiness.industryRehabilitationHemodynamics[SPI.MECA.BIOM]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Biomechanics [physics.med-ph]StiffnessPatient specificAscending thoracic aortic aneurysmmedicine.diseaseNoninvasive inverse method020601 biomedical engineeringAortic AneurysmAortic ValveCardiologyAortic stiffnessmedicine.symptombusiness030217 neurology & neurosurgeryJournal of Biomechanics
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct